Segal Lloyd Mitchell sold AKTS
January 12, 2026 · Form 4 insider transaction
Segal Lloyd Mitchell sold 24,687 shares of Aktis Oncology, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.
Footnotes
The Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 3.8044-for-1 basis immediately prior to the closing of the Issuer's initial public offering of its Common Stock.; Consists of shares held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.